GlassScriptPhysician profile
Kary A Krochko
NPI 1295904225
$5,692.32
in general payments reported to CMS, 2019-2025
25 companies · $664 in 2025
The $664 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,659 · 2022: $1,741 · 2023: $954 · 2024: $674 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,078.68 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $744.93 | 2021-2023 | Ztlido |
| Uswm, LLC | $741.47 | 2021-2023 | Lucemyra, Zimhi |
| Collegium Pharmaceutical, INC. | $718.40 | 2021-2025 | Belbuca, Xtampza |
| Abbvie INC. | $450.93 | 2021-2024 | |
| Indivior INC. | $367.09 | 2023-2025 | Sublocade |
| Ardelyx, INC. | $199.22 | 2024-2025 | Ibsrela |
| Almatica Pharma LLC | $199.13 | 2021-2023 | Gralise |
| Azurity Pharmaceuticals, INC. | $197.76 | 2024-2025 | Horizant |
| Teva Pharmaceuticals USA, INC. | $169.70 | 2021 | |
| Hikma Pharmaceuticals USA | $151.49 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $122.03 | 2021 | |
| Redhill Biopharma INC. | $111.26 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $95.23 | 2021 | |
| Pfizer INC. | $66.47 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $56.47 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $52.65 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $37.66 | 2021 | |
| Alkermes, INC. | $25.28 | 2023 | Vivitrol |
| Allergan, INC. | $21.10 | 2021 | |
| Lundbeck LLC | $19.70 | 2021 | |
| Averitas Pharma INC. | $17.44 | 2023 | Qutenza |
| Biodelivery Sciences International, INC. | $17.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.59 | 2022 | |
| Lilly USA, LLC | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kary Krochko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.